Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pneumococcal conjugate vaccines are highly effective in reducing vaccine-type pneumococcal disease but are expensive. Fractional-dose vaccines may help sustain vaccine programs. New research ...

In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a ...

After pneumococcal disease and colonization have been controlled through vaccination campaigns ... those who were 2 to 6 months of age received three doses, those who were 7 to 18 months of ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...

pneumococcal pneumonia and empyema among children of ages targeted to receive vaccine. Data on 2- and 3-dose schedules were included. Percent change of pneumonia incidence rates from baseline to ...

Vaxcyte has commenced the Phase II trial of its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31, in healthy infants, with the first subjects receiving the dose. The study aims to ...

Opens in a new tab or window The Gram-positive bacterium known as Streptococcus pneumoniae causes pneumococcal ... vaccine. For patients this means that the current UK guidance for a single dose ...

Interlaboratory comparisons have proved that the 2 laboratories give concordant results. GMCs of Anti-Pneumococcal PS Antibodies Reported in This Study, Compared With Those Published for 4-Dose ...